Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

Earlier we have shown the expression of a constitutively active receptor tyrosine kinase Axl in CLL B-cells from previously untreated CLL patients, and that Axl inhibitor TP-0903 induces robust leukemic B-cell death. To explore whether Axl is an effective target in relapsed/refractory CLL patients,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Sinha, Sutapa, Boysen, Justin C., Chaffee, Kari G., Kabat, Brian F., Slager, Susan L., Parikh, Sameer A., Secreto, Charla R., Call, Tim, Shanafelt, Tait D., Leis, Jose F., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324680/
https://ncbi.nlm.nih.gov/pubmed/30647852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26444
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars